Comparison of Efficacy in Patients with Metastatic Melanoma Treated with Ipilimumab and Nivolumab Who Did or Did Not Discontinue Treatment Due to Immune-Related Adverse Events: A Real-World Data Study.

Saved in:

Bibliographic Details
Title:	Comparison of Efficacy in Patients with Metastatic Melanoma Treated with Ipilimumab and Nivolumab Who Did or Did Not Discontinue Treatment Due to Immune-Related Adverse Events: A Real-World Data Study.
Authors:	Fink, Morten¹ (AUTHOR) anders.vittrup@oncology.au.dk, Vittrup, Anders Schwartz¹ (AUTHOR) louise.guldbrandt@midt.rm.dk, Bastholt, Lars² (AUTHOR) Lars.Bastholt@rsyd.dk, Svane, Inge Marie³ (AUTHOR) Inge.Marie.Svane@regionh.dk, Donia, Marco³ (AUTHOR) marco.donia@regionh.dk, Luczak, Adam A.⁴ (AUTHOR) adal@rn.dk, Ruhlmann, Christina H.⁵ (AUTHOR) christina.ruhlmann@rsyd.dk, Guldbrandt, Louise Mahncke¹ (AUTHOR) uhk@braintrust-consult.dk, Koehler, Ulrich Heide¹ (AUTHOR) henrschm@rm.dk, Winther, Mette Lerche² (AUTHOR) mette.winther@hotmail.dk, Ellebaek, Eva³ (AUTHOR) eva.ellebaek.steensgaard@regionh.dk, Haslund, Charlotte Aaquist⁴ (AUTHOR) cah@rn.dk, Schmidt, Henrik¹ (AUTHOR)
Source:	Cancers. Nov2021, Vol. 13 Issue 21, p5550. 1p.
Database:	Academic Search Ultimate

Description
ISSN:	20726694
DOI:	10.3390/cancers13215550